RecruitingPhase 2

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

United States52 participantsStarted 2025-09-15

Plain-language summary

This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score \<55.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Is \<2 years old at the time of the informed consent
✓. Had a gestational age of ≥35 weeks and gestational body weight ≥2.0 kg at birth
✓. Has confirmed diagnosis of 5q autosomal recessive SMA
✓. Has confirmed presence of SMN2 gene copy(ies)
✓. Must have been treated with an approved SMN1-targeted therapy (ie, onasemnogene abeparvovec-xioi) or are continuing to be treated with an approved SMN2-targeted therapy (ie, nusinersen or risdiplam)
✓. Body weight for age is no less than 1st percentile based on the WHO Child Growth Standards at the Screening Visit
✓. Has delayed motor milestones for age attributed to SMA at the discretion of the Investigator or a CHOP-INTEND score \<55

Exclusion criteria

✕. Nutritional status that is not anticipated to be stable throughout the study or medical necessity for a gastric feeding tube, where most feeds are administered by this route
✕. Major orthopedic issues such as severe scoliosis or severe contractures or interventional procedure, including spine or hip surgery, which is considered to have the potential to substantially limit the ability of the subject to be evaluated on any motor function outcome measures, within 6 months before Screening or anticipated during the study
✕. Any other physical limitations (eg, the subject requires cast for contractures) that would prevent the subject from undergoing motor function outcome measures throughout the study.

What they're measuring

Evaluate the PK of apitegromab in subjects <2 years old with SMA

Timeframe: 52 Weeks

Evaluate the PD of apitegromab in subjects <2 years old with SMA

Timeframe: 52 Weeks

Evaluate the motor function outcomes (ie, efficacy) due to apitegromab treatment

Timeframe: 48 Weeks

Trial details

NCT IDNCT07047144

SponsorScholar Rock, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-11

Contact for this trial

Scholar Rock

857-259-3860 MedicalInformation@scholarrock.com

View on ClinicalTrials.gov More Spinal Muscular Atrophy trials